Navigation Links
Cytopia's CYT387 Receives FDA Clearance to Start US Clinical Trials
Date:9/3/2009

mmittee approval.

"Approval of the company's second IND marks another milestone in the development of Cytopia's suite of small molecule drugs," said Mr. Andrew Macdonald, CEO. "With a strong package of preclinical data, the prospects for CYT387 are excellent and we look forward to commencing the clinical trial with Dr. Tefferi at the Mayo Clinic later this year."

There has been considerable commercial interest in the JAK2 target with no selective JAK inhibitors having yet successfully completed late stage clinical trials and few compounds in development that meet a desirable product profile. Cytopia will seek to develop CYT387 through a commercial partnership and has been in discussions with potential partners for some time. A similar JAK2 inhibitor in clinical development was recently licensed by Onyx Pharmaceuticals for $550 million including a $25 million up-front payment and double-digit royalties.

About Cytopia

Cytopia Ltd is an Australian biotechnology company focused on the discovery and development of new drugs to treat cancer and other diseases. Cytopia conducts its research and drug development through subsidiaries based in Melbourne, Australia and California, USA and specializes in developing new small molecule compounds with an improved therapeutic profile for the treatment of cancer.

The company's lead drug candidate is CYT997, a vascular disrupting agent (VDA) for the treatment of various cancers, which is currently being trialled in Phase II clinical studies. Cytopia is continuing to build on its range of JAK inhibitors and kinase expertise, with CYT387, a novel oral JAK1/JAK2 inhibitor focused on the treatment of myeloproliferative disorders, to enter Phase I clinical studies in 2009.

www.cytopia.com.au


'/>"/>
SOURCE Cytopia Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Stemedica Achieves Major Milestone - Company Receives License to Manufacture Clinical Grade Stem Cells
2. Families of Spinal Muscular Atrophy Receives FDA Orphan Drug Designation For Quinazoline495 For The Treatment of Spinal Muscular Atrophy
3. Mennen Medical Receives Frost & Sullivan 2009 European Patient Monitoring Technology Leadership Award
4. WorldHeart Receives US Clinical Study Approval for the Levacor(TM) VAD
5. Covance Receives Highest Level of Phase I Accreditation
6. Worlds First Cardiac Adult Stem Cell Patient Receives Infusion
7. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
8. Cystic Fibrosis - Liposomal Tobramycin Receives Second Orphan Drug Designation Within Weeks
9. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
10. USC Keck School of Medicines Dr. Alan Epstein Receives Prestigious National Cancer Institute RAID Award for Breakthrough IL-2 Molecule Therapeutic
11. Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... , March 3, 2015 Konica Minolta ... announced today a new, integrated portable X-ray ... solution is now available with a larger integrated console, ... mounted system offers a larger viewing area to simplify ... provides additional space for accessories and storage, along with ...
(Date:3/3/2015)... 3, 2015  Columbia Laboratories, Inc. (Nasdaq: ... Company"), a specialty pharmaceutical company focused on pharmaceuticals for ... the 27th Annual ROTH Conference, which will take place ... Dana Point, California . Management,s presentation ... a.m. Pacific Time (12:00 p.m. Eastern Time) in the ...
(Date:3/3/2015)... 2015  Web Industries, Inc., a leading provider ... Medical Device, Advanced Composites, Consumer Products, and Wire ... Medical Specialties Preferred Converter by 3M,s Medical Specialties ... to streamline their supply chains by using Web ... materials, intermediate converting services, and contract manufacturing and ...
Breaking Medicine Technology:Konica Minolta Medical Imaging and Shimadzu Medical Systems USA Introduce MobileArt Evolution EFX AeroDR-i with 17" Touch Monitor to Simplify Operation 2Konica Minolta Medical Imaging and Shimadzu Medical Systems USA Introduce MobileArt Evolution EFX AeroDR-i with 17" Touch Monitor to Simplify Operation 3Web Industries Receives 3M Preferred Converter Status 2
... advanced leukemia and myelodysplastic, syndrome patients presented ... N.J., Dec. 10 Celator Pharmaceuticals today,announced results ... a liposomal,formulation that incorporates a synergistic ratio of ... and myelodysplastic,syndromes. While dose escalation in the study ...
... Dec. 10 The US Food and,Drug Administration ... small,open, long-term, clinical studies in patients with gastro-esophageal ... study) or NEXIUM(R) (LOTUS study) treatment., AstraZeneca ... conclusion which states,"FDA continues to conclude that long-term ...
Cached Medicine Technology:Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients 2FDA Concludes There is No Increased Risk of Cardiac Events for Patients Treated with omeprazole and NEXIUM(R) (esomeprazole magnesium) 2FDA Concludes There is No Increased Risk of Cardiac Events for Patients Treated with omeprazole and NEXIUM(R) (esomeprazole magnesium) 3FDA Concludes There is No Increased Risk of Cardiac Events for Patients Treated with omeprazole and NEXIUM(R) (esomeprazole magnesium) 4
(Date:3/3/2015)... Daylight Savings Time may lead to your kids ... for parents. , Parents and their children may feel a ... they set their clocks forward one hour for Daylight Savings ... one hour earlier -- you will have already lost one ... about “sleep hygiene” for their kids and teens this week, ...
(Date:3/3/2015)... 03, 2015 Topical BioMedics, Inc., announces its ... streamed live on Tuesday, March 10th, 12pm – 1pm and ... and accessible 24/7. , The Pain Management ... for the March 10th workshop is “Opioid Addiction: An ... the U.S. represents 5% of the world’s population, yet consumers ...
(Date:3/3/2015)... MD (PRWEB) March 03, 2015 Today ... Association (ASHA) is using the occasion to applaud and ... campaign by the World Health Organization (WHO) for stemming ... campaign aims to encourage young people to practice safe ... audio technology, attending concerts or sporting events, or engaging ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 The ... better predict antidepressant treatment outcomes for patients with ... than any of the individual genes that comprise ... investigators from the Mayo Clinic and Assurex Health, ... , The proprietary technology of the GeneSight ...
(Date:3/3/2015)... With a grant of more than $4.5 ... has been named a national coordinating center by the ... for Health: Improving Community Health Through Innovations in Financing ... health and reduce disparities through innovations in collaboration and ... of the center and up to 10 communities over ...
Breaking Medicine News(10 mins):Health News:Don’t Let Daylight Savings Disrupt Your Child’s Sleep 2Health News:Topical BioMedics Hosts March Pain Management Webinar 2Health News:Topical BioMedics Hosts March Pain Management Webinar 3Health News:Topical BioMedics Hosts March Pain Management Webinar 4Health News:Topical BioMedics Hosts March Pain Management Webinar 5Health News:ASHA Applauds Launch of New WHO Campaign 2Health News:GeneSight Multi-Gene Combinatorial Pharmacogenomic (CPGx™) Test is More Predictive of Antidepressant Response than Single Gene Tests 2Health News:GeneSight Multi-Gene Combinatorial Pharmacogenomic (CPGx™) Test is More Predictive of Antidepressant Response than Single Gene Tests 3Health News:GeneSight Multi-Gene Combinatorial Pharmacogenomic (CPGx™) Test is More Predictive of Antidepressant Response than Single Gene Tests 4Health News:GeneSight Multi-Gene Combinatorial Pharmacogenomic (CPGx™) Test is More Predictive of Antidepressant Response than Single Gene Tests 5Health News:GeneSight Multi-Gene Combinatorial Pharmacogenomic (CPGx™) Test is More Predictive of Antidepressant Response than Single Gene Tests 6Health News:Robert Wood Johnson Foundation Names Georgia Health Policy Center National Center for Bridging for Health Initiative 2
... have now proved using a specialized mouse model that ... neurons.// The results of this study have for the ... ,Also known as apoE, this cholesterol-carrying protein ... the major known genetic risk factor for Alzheimer's disease, ...
... published in the journal Carcinogenesis show that exercise can offer ... that had a round the clock access to wheels took ... that exercise and a restricted diet had a healthy effect ... ,The first study exposed mice to ultraviolet B ...
... Dental Health Foundation has found that more than 60 percent ... clean off food debris// struck in between their teeth. Items ... use, the survey said. ,More disturbingly, the survey ... teeth giving rise to oral health problems and bad breath. ...
... the form of health claims that green tea is no ... a model qualified health// claim says "Daily consumption of at ... a source of catechins may reduce a number of risk ... evidence is supportive, but not conclusive, for this claim. (Green ...
... (AIIMS) here is running short of faculty members and its ... informed Friday. ,Replying to a question, minister of state ... AIIMS was running with just 479 faculty members as against ... the house that during 2003-05, 20 faculty members had either ...
... rate in Madhya Pradesh, Bhopal Archbishop Pascal Topno has ... ,With 13,000 reported deaths every year during or ... is one of the highest in the country. ... Niketan Welfare Centre here, Topno urged them to tap ...
Cached Medicine News:Health News:Alzheimer's-linked apolipoprotein E produced by neurons, Gladstone study 2Health News:Green tea’s health claims questioned: FD 2Health News:Green tea’s health claims questioned: FD 3
Cushing bayonet....
Straight, blunt tips....
Angled, pointed, with attached cable for Valleylab and other brands generators....
Autoclavable reusable pencil for Aaron 800 & 1200 - comes with generator or 1/box....
Medicine Products: